{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:49:37Z","timestamp":1793148577429,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21NS 095047"],"award-info":[{"award-number":["R21NS 095047"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS 086134"],"award-info":[{"award-number":["R01 NS 086134"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UH2 NS092981"],"award-info":[{"award-number":["UH2 NS092981"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ebiom.2020.102735","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T01:03:11Z","timestamp":1586480591000},"page":"102735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7072-064X","authenticated-orcid":false,"given":"Ying","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengtao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venette","family":"Fannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Blackwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold W.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2020.102735_bib0001","series-title":"The online metabolic and molecular bases of inherited diseases","article-title":"Gaucher disease","author":"Grabowski","year":"2010"},{"key":"10.1016\/j.ebiom.2020.102735_bib0002","series-title":"Williams hematology","article-title":"Gaucher disease and related lysosomal storage diseases","author":"Zimran","year":"2016"},{"key":"10.1016\/j.ebiom.2020.102735_bib0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1749-6632.1998.tb09667.x","article-title":"Sphingolipid metabolism. sphingoid analogs, sphingolipid activator proteins, and the pathology of the cell","volume":"845","author":"Sandhoff","year":"1998","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.ebiom.2020.102735_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bcmd.2010.08.012","article-title":"Type 2 gaucher disease: phenotypic variation and genotypic heterogeneity","volume":"46","author":"Gupta","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2020.102735_bib0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00690463","article-title":"Neuropathology of the norrbottnian type of Gaucher disease. Morphological and biochemical studies","volume":"65","author":"Conradi","year":"1984","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.ebiom.2020.102735_bib0006","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1212\/01.wnl.0000230215.41296.18","article-title":"Glucocerebrosidase mutations are an important risk factor for Lewy body disorders","volume":"67","author":"Goker-Alpan","year":"2006","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ebiom.2020.102735_bib0007","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/mds.22538","article-title":"The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism","volume":"24","author":"DePaolo","year":"2009","journal-title":"Movement disord"},{"issue":"1","key":"10.1016\/j.ebiom.2020.102735_bib0008","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102735_bib0009","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/MOP.0b013e32834c20d9","article-title":"Enzyme replacement therapy for lysosomal storage diseases","volume":"23","author":"Lachmann","year":"2011","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.ebiom.2020.102735_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta P\u00e6diatrica"},{"issue":"9","key":"10.1016\/j.ebiom.2020.102735_bib0011","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher disease and its treatment options","volume":"47","author":"Bennett","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.ebiom.2020.102735_bib0012","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2014.08.011","article-title":"CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings","volume":"114","author":"Burrow","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.ebiom.2020.102735_bib0013","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2020.102735_bib0014","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","article-title":"Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study","volume":"51","author":"Kuter","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102735_bib0015","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.ebiom.2020.102735_bib0016","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol Ther"},{"issue":"29","key":"10.1016\/j.ebiom.2020.102735_bib0017","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.ebiom.2020.102735_bib0018","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","article-title":"Fetal gene therapy for neurodegenerative disease of infants","volume":"24","author":"Massaro","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ebiom.2020.102735_bib0019","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat Chem Biol"},{"issue":"35","key":"10.1016\/j.ebiom.2020.102735_bib0020","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J Biol Chem"},{"issue":"28","key":"10.1016\/j.ebiom.2020.102735_bib0021","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces alpha-Synuclein and glycolipid levels in iPSC-Derived dopaminergic neurons from patients with Gaucher disease and parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J Neurosci"},{"issue":"12","key":"10.1016\/j.ebiom.2020.102735_bib0022","doi-asserted-by":"crossref","first-page":"6874","DOI":"10.1074\/jbc.271.12.6874","article-title":"Functional organization of saposin C. Definition of the neurotrophic and acid beta-glucosidase activation regions","volume":"271","author":"Qi","year":"1996","journal-title":"J Biol Chem"},{"issue":"34","key":"10.1016\/j.ebiom.2020.102735_bib0023","doi-asserted-by":"crossref","first-page":"31918","DOI":"10.1074\/jbc.M302752200","article-title":"Saposin c is required for normal resistance of acid beta-glucosidase to proteolytic degradation","volume":"278","author":"Sun","year":"2003","journal-title":"J Biol Chem"},{"issue":"41","key":"10.1016\/j.ebiom.2020.102735_bib0024","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1021\/bi401191v","article-title":"Saposin C protects glucocerebrosidase against alpha-synuclein inhibition","volume":"52","author":"Yap","year":"2013","journal-title":"Biochemistry"},{"issue":"24","key":"10.1016\/j.ebiom.2020.102735_bib0025","doi-asserted-by":"crossref","first-page":"16746","DOI":"10.1016\/S0021-9258(19)89454-1","article-title":"Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins c with acid beta-glucosidase","volume":"269","author":"Qi","year":"1994","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ebiom.2020.102735_bib0026","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s004010050960","article-title":"Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant","volume":"97","author":"Pampols","year":"1999","journal-title":"Acta Neuropathol (Berl)"},{"issue":"15","key":"10.1016\/j.ebiom.2020.102735_bib0027","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/hmg\/ddq204","article-title":"Saposin c mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin c deficiency, but normal prosaposin processing and sorting","volume":"19","author":"Vaccaro","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ebiom.2020.102735_bib0028","series-title":"The metabolic and molecular bases of inherited disease. iii","first-page":"3371","article-title":"Sphingolipid activator proteins","author":"Sandhoff","year":"2000"},{"issue":"3","key":"10.1016\/j.ebiom.2020.102735_bib0029","doi-asserted-by":"crossref","first-page":"e33966","DOI":"10.1371\/journal.pone.0033966","article-title":"Saposin C coupled lipid nanovesicles specifically target arthritic mouse joints for optical imaging of disease severity","volume":"7","author":"Qi","year":"2012","journal-title":"PLoS ONE"},{"issue":"16","key":"10.1016\/j.ebiom.2020.102735_bib0030","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.18632\/oncotarget.2214","article-title":"Phosphatidylserine-selective targeting and anticancer effects of SAPC-dops nanovesicles on brain tumors","volume":"5","author":"Blanco","year":"2014","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ebiom.2020.102735_bib0031","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/mt.2013.114","article-title":"Systemic delivery of SAPC-dops has antiangiogenic and antitumor effects against glioblastoma","volume":"21","author":"Wojton","year":"2013","journal-title":"Mol Ther"},{"issue":"18","key":"10.1016\/j.ebiom.2020.102735_bib0032","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1158\/1078-0432.CCR-08-3285","article-title":"Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein","volume":"15","author":"Qi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ebiom.2020.102735_bib0033","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1074\/jbc.M511110200","article-title":"Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations","volume":"281","author":"Liou","year":"2006","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ebiom.2020.102735_bib0034","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0005-2760(76)90258-7","article-title":"Effects of detergents and choline-containing phospholipids on human spleen glucocerebrosidase","volume":"431","author":"Blonder","year":"1976","journal-title":"Biochim Biophys Acta"},{"issue":"6377","key":"10.1016\/j.ebiom.2020.102735_bib0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/357407a0","article-title":"Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene","volume":"357","author":"Tybulewicz","year":"1992","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102735_bib0036","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/hmg\/ddp580","article-title":"Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits","volume":"19","author":"Sun","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.ebiom.2020.102735_bib0037","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/hmg\/ddp531","article-title":"Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse","volume":"19","author":"Sun","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.ebiom.2020.102735_bib0038","first-page":"769","article-title":"A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease","volume":"9","author":"Westbroek","year":"2016","journal-title":"Dis Model Mech"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102735_bib0039","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1086\/498652","article-title":"The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy","volume":"77","author":"Du","year":"2005","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.ebiom.2020.102735_bib0040","first-page":"15","article-title":"Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting","volume":"40","author":"Fabbro","year":"1987","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.ebiom.2020.102735_bib0041","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/84651","article-title":"Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3","volume":"7","author":"Makinen","year":"2001","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ebiom.2020.102735_bib0042","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1084\/jem.20142290","article-title":"A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules","volume":"212","author":"Aspelund","year":"2015","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.ebiom.2020.102735_bib0043","doi-asserted-by":"crossref","first-page":"e57560","DOI":"10.1371\/journal.pone.0057560","article-title":"Substrate compositional variation with tissue\/region and GBA1 mutations in mouse models\u2013implications for Gaucher disease","volume":"8","author":"Sun","year":"2013","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.ebiom.2020.102735_bib0044","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.ebiom.2020.102735_bib0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2004.11.054","article-title":"Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons","volume":"1035","author":"Schmued","year":"2005","journal-title":"Brain Res"},{"issue":"23","key":"10.1016\/j.ebiom.2020.102735_bib0046","first-page":"5126","article-title":"Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice","volume":"25","author":"Liou","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"29","key":"10.1016\/j.ebiom.2020.102735_bib0047","doi-asserted-by":"crossref","first-page":"27010","DOI":"10.1074\/jbc.M101075200","article-title":"Differential membrane interactions of saposins A and C: implications for the functional specificity","volume":"276","author":"Qi","year":"2001","journal-title":"J Biol Chem"},{"issue":"33","key":"10.1016\/j.ebiom.2020.102735_bib0048","doi-asserted-by":"crossref","first-page":"11544","DOI":"10.1021\/bi980785+","article-title":"Acid beta-glucosidase: intrinsic fluorescence and conformational changes induced by phospholipids and saposin C","volume":"37","author":"Qi","year":"1998","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.ebiom.2020.102735_bib0049","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1203\/00006450-199602000-00021","article-title":"Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues","volume":"39","author":"Xu","year":"1996","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ebiom.2020.102735_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymeth.2018.02.003","article-title":"Thermophoresis for characterizing biomolecular interaction","author":"Asmari","year":"2018","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.ebiom.2020.102735_bib0051","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.abb.2004.02.023","article-title":"Fusogenic domain and lysines in saposin C","volume":"424","author":"Qi","year":"2004","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"10.1016\/j.ebiom.2020.102735_bib0052","first-page":"365","article-title":"Characterization of mutations in Gaucher patients by cDNA cloning","volume":"44","author":"Wigderson","year":"1989","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.ebiom.2020.102735_bib0053","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/BF00711365","article-title":"Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease","volume":"17","author":"Brady","year":"1994","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.ebiom.2020.102735_bib0054","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/glycob\/cwm008","article-title":"Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease","volume":"17","author":"Van Patten","year":"2007","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.ebiom.2020.102735_bib0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1014915430398","article-title":"Uptake of mannose-terminal glucocerebrosidase in cultured human cholinergic and dopaminergic neuron cell lines","volume":"27","author":"Schueler","year":"2002","journal-title":"Neurochem Res"},{"issue":"5","key":"10.1016\/j.ebiom.2020.102735_bib0056","doi-asserted-by":"crossref","first-page":"e10750","DOI":"10.1371\/journal.pone.0010750","article-title":"Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model","volume":"5","author":"Xu","year":"2010","journal-title":"PLoS ONE"},{"issue":"24","key":"10.1016\/j.ebiom.2020.102735_bib0057","first-page":"7031","article-title":"Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model","volume":"24","author":"Dasgupta","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"5860","key":"10.1016\/j.ebiom.2020.102735_bib0058","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1126\/science.1152066","article-title":"Membrane phosphatidylserine regulates surface charge and protein localization","volume":"319","author":"Yeung","year":"2008","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ebiom.2020.102735_bib0059","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1074\/jbc.M705195200","article-title":"Crystal structure of lactadherin C2 domain at 1.7A resolution with mutational and computational analyses of its membrane-binding motif","volume":"283","author":"Shao","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ebiom.2020.102735_bib0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbamem.2004.09.006","article-title":"Lactadherin binds selectively to membranes containing phosphatidyl-L-serine and increased curvature","volume":"1667","author":"Shi","year":"2004","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"10.1016\/j.ebiom.2020.102735_bib0061","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tins.2016.07.001","article-title":"How do meningeal lymphatic vessels drain the CNS?","volume":"39","author":"Raper","year":"2016","journal-title":"Trends Neurosci"},{"issue":"4","key":"10.1016\/j.ebiom.2020.102735_bib0062","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/ar1191","article-title":"Phosphatidylserine receptor and apoptosis: consequences of a non-ingested meal","volume":"6","author":"Botto","year":"2004","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2020.102735_bib0063","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1091\/mbc.e03-09-0668","article-title":"Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production","volume":"15","author":"Brouckaert","year":"2004","journal-title":"Mol Biol Cell"},{"issue":"8","key":"10.1016\/j.ebiom.2020.102735_bib0064","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.tem.2010.04.003","article-title":"Lymphatic lipid transport: sewer or subway?","volume":"21","author":"Dixon","year":"2010","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102735_bib0065","doi-asserted-by":"crossref","first-page":"E1183","DOI":"10.1152\/ajpendo.90899.2008","article-title":"Intestinal lipid absorption","volume":"296","author":"Iqbal","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ebiom.2020.102735_bib0066","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1096-7192(02)00040-9","article-title":"Ex vivo localization of the mouse saposin C activation region for acid beta-glucosidase","volume":"76","author":"Qi","year":"2002","journal-title":"Mol Genet Metab"},{"issue":"9","key":"10.1016\/j.ebiom.2020.102735_bib0067","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1515\/bchm3.1986.367.2.879","article-title":"Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. absence of one of them in a human Gaucher disease variant","volume":"367","author":"Christomanou","year":"1986","journal-title":"Biol Chem Hoppe Seyler."},{"issue":"19","key":"10.1016\/j.ebiom.2020.102735_bib0068","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/BF01716064","article-title":"Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder","volume":"67","author":"Christomanou","year":"1989","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.ebiom.2020.102735_bib0069","article-title":"A rare form of Gaucher disease resulting from saposin C deficiency","author":"Kang","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"7643","key":"10.1016\/j.ebiom.2020.102735_bib0070","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature21368","article-title":"Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease","volume":"543","author":"Pandey","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ebiom.2020.102735_bib0071","doi-asserted-by":"crossref","first-page":"e19037","DOI":"10.1371\/journal.pone.0019037","article-title":"Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS ONE"},{"issue":"suppl","key":"10.1016\/j.ebiom.2020.102735_bib0072","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1200\/JCO.2018.36.15_suppl.2517","article-title":"First-in-human, first-in-class phase 1a study of BXQ-350 for solid tumors and gliomas","volume":"36","author":"Rixe","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.ebiom.2020.102735_bib0073","doi-asserted-by":"crossref","first-page":"e14533","DOI":"10.1200\/JCO.2018.36.15_suppl.e14533","article-title":"Absence of indicators of hypercoagulability and antiphospholipid syndrome in bxq-350 first in human study","volume":"36","author":"Cruze","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Pt 9","key":"10.1016\/j.ebiom.2020.102735_bib0074","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/brain\/awv179","article-title":"Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations","volume":"138","author":"Alcalay","year":"2015","journal-title":"Brain: J Neurol"},{"issue":"Pt 3","key":"10.1016\/j.ebiom.2020.102735_bib0075","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain: J Neurol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396420301109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396420301109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:32:19Z","timestamp":1778873539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396420301109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":75,"alternative-id":["S2352396420301109"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2020.102735","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2020.102735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102735"}}